+

WO2013152352A8 - Vecteur de la rubéole atténué, vivant, pour exprimer des antigènes de vaccin - Google Patents

Vecteur de la rubéole atténué, vivant, pour exprimer des antigènes de vaccin Download PDF

Info

Publication number
WO2013152352A8
WO2013152352A8 PCT/US2013/035634 US2013035634W WO2013152352A8 WO 2013152352 A8 WO2013152352 A8 WO 2013152352A8 US 2013035634 W US2013035634 W US 2013035634W WO 2013152352 A8 WO2013152352 A8 WO 2013152352A8
Authority
WO
WIPO (PCT)
Prior art keywords
rubella
structural protein
antigenic insert
antigenic
orf
Prior art date
Application number
PCT/US2013/035634
Other languages
English (en)
Other versions
WO2013152352A1 (fr
Inventor
Ira Berkower
Konstantin VIRNIK
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority to US14/387,514 priority Critical patent/US9566329B2/en
Publication of WO2013152352A1 publication Critical patent/WO2013152352A1/fr
Publication of WO2013152352A8 publication Critical patent/WO2013152352A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des constructions de vecteur viral de la rubéole isolé qui comprennent un cadre de lecture ouvert (ORF) de protéine non structurale de la rubéole sans délétion dans le cadre, un ORF de protéine structurale de la rubéole et un insert antigénique hétérologue. Selon un exemple, l'insert antigénique hétérologue est positionné à l'intérieur de l'ORF de protéine structurale de la rubéole. Selon certains exemples, l'insert antigénique hétérologue est positionné dans l'ORF de protéine structurale de la rubéole entre un gène codant pour la protéine structurale E2 et un gène codant pour la protéine structurale E1. Des inserts antigéniques illustratifs comprennent des antigènes de surface du VIH, du SIV, du RSV ou de l'hépatite B. Selon certains exemples, l'insert antigénique du VIH est un insert antigénique Gag, un insert antigénique gp41 ou un insert antigénique gpl20. L'invention concerne également des utilisations du vecteur viral de la rubéole isolé afin d'induire une réponse immunitaire à un virus particulier, tel que le VIH 1, pour tester la sensibilité à des anticorps de neutralisation, ou pour le criblage de médicaments antiviraux (tels que des inhibiteurs de protéase).
PCT/US2013/035634 2012-04-06 2013-04-08 Vecteur de la rubéole atténué, vivant, pour exprimer des antigènes de vaccin WO2013152352A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/387,514 US9566329B2 (en) 2012-04-06 2013-04-08 Live, attenuated rubella vector to express vaccine antigens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261621394P 2012-04-06 2012-04-06
US61/621,394 2012-04-06
US201261642333P 2012-05-03 2012-05-03
US61/642,333 2012-05-03

Publications (2)

Publication Number Publication Date
WO2013152352A1 WO2013152352A1 (fr) 2013-10-10
WO2013152352A8 true WO2013152352A8 (fr) 2013-11-07

Family

ID=48183001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/035634 WO2013152352A1 (fr) 2012-04-06 2013-04-08 Vecteur de la rubéole atténué, vivant, pour exprimer des antigènes de vaccin

Country Status (2)

Country Link
US (1) US9566329B2 (fr)
WO (1) WO2013152352A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138852A1 (fr) 2014-03-14 2015-09-17 University Of Washington Éléments isolateurs génomiques et leurs utilisations
WO2024242637A1 (fr) * 2023-05-24 2024-11-28 Nanyang Technological University Nouvel arn à auto-amplification

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
DE3751908T2 (de) 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
CA1323293C (fr) 1987-12-11 1993-10-19 Keith C. Backman Essai utilisant la reorganisation d'une sonde a l'acide nucleique dependant d'une matrice
WO1990001069A1 (fr) 1988-07-20 1990-02-08 Segev Diagnostics, Inc. Procede d'amplification et de detection de sequences d'acide nucleique
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6958237B2 (en) 1991-06-28 2005-10-25 Georgia State Univesity Research Foundation, Inc. Highly infectious rubella virus DNA constructs and methods of production
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
WO1993001831A1 (fr) 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Induction de reponses de lymphocytes t cytotoxiques
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
CA2129514A1 (fr) 1992-03-12 1993-09-16 M. Amin Khan Acth a liberation controlee, contenant des microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
PT776376E (pt) 1994-07-15 2002-05-31 Organon Teknika Bv Utilizacao de arn-polimerase para melhorar o processo de amplificacao de acido nucleico
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US7202354B2 (en) 2001-03-30 2007-04-10 Abbott Laboratories Hepatitis B virus surface antigen mutant and methods of detection thereof
AU2003254093A1 (en) 2002-07-19 2004-02-09 Isis Pharmaceuticals, Inc. Methods for mass spectrometry analysis utilizing an integrated microfluidics sample platform
JP4898434B2 (ja) 2003-06-20 2012-03-14 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー Ｂ型肝炎ウィルスの新規の表面タンパク質（ＨＢｓＡｇ）変異体
WO2011047340A1 (fr) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Insertion de gènes étrangers dans le virus de la rubéole et leur expression stable dans un vaccin viral vivant atténué

Also Published As

Publication number Publication date
US20150079123A1 (en) 2015-03-19
WO2013152352A1 (fr) 2013-10-10
US9566329B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
Jansen et al. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination
Enjuanes et al. Molecular basis of coronavirus virulence and vaccine development
Margine et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses
MX387666B (es) Composiciones y su uso en el tratamiento de citomegalovirus
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
WO2016109792A3 (fr) Nouveaux vaccins multivalents à base de nanoparticules
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2015142671A3 (fr) Vecteurs du virus de la grippe et leurs utilisations
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
EA201492110A1 (ru) Вакцины против впг-2
WO2015052543A3 (fr) Vaccination antipaludique
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
MX2022003664A (es) Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
WO2015195218A8 (fr) Particules pseudo-virales (ppv) grippales polyvalentes, et leur utilisation comme vaccins
WO2016130560A3 (fr) Déterminants antigéniques des lymphocytes t à réactivité croisée du vih, du vis et du vif pour vaccins pour l'être humain et le chat
HRP20171697T1 (hr) Varijanta hiv gp-120
WO2007046839A3 (fr) Nouveaux vaccins a base de virus vivant
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
WO2013152352A8 (fr) Vecteur de la rubéole atténué, vivant, pour exprimer des antigènes de vaccin
WO2016149643A3 (fr) Protéines de fusion comprenant des glycoprotéines de surface d'alpha virus et un antigène associé à une tumeur, et procédés associés
WO2017053525A3 (fr) Vaccin et thérapie contre la grippe
WO2011041788A3 (fr) Virus de l'hépatite virale du dindon et utilisations de celui-ci
IN2014DN07152A (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13718434

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14387514

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13718434

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载